Optimal Use of the Non-Inferiority Trial Design

被引:28
作者
Angeli, Fabio [1 ,2 ]
Verdecchia, Paolo [3 ]
Vaudo, Gaetano [4 ]
Masnaghetti, Sergio [2 ]
Reboldi, Gianpaolo [4 ]
机构
[1] Univ Insubria, Dept Med & Surg, Varese, Italy
[2] IRCCS Tradate, Dept Med & Cardiopulm Rehabil, Maugeri Care & Res Inst, Varese, Italy
[3] Hosp S Maria Misericordia, Div Cardiol, Fdn Umbra Cuore & Ipertens ONLUS, Perugia, Italy
[4] Univ Perugia, Dept Med, I-06156 Perugia, Italy
关键词
DIRECT THROMBIN INHIBITOR; NONINFERIORITY; DABIGATRAN; WARFARIN;
D O I
10.1007/s40290-020-00334-z
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Superiority trials are conducted to test the hypothesis that a treatment or strategy A is superior to (i.e., better than) treatment strategy B in reducing the impact of disease. However, A may be considerably safer, more convenient, or cheaper than B. These features may make A more attractive than B even if the burden of disease is reduced comparably by the two treatments, or even a bit worse by A over B. In this context, non-inferiority trials have become increasingly popular to test the hypothesis that a new treatment is not 'unacceptably worse' than an active comparator by more than a predefined non-inferiority margin. Non-inferiority trials have unique design features and methodology and require a different analysis than traditional superiority trials. The main aim of this overview is to analyze the role of non-inferiority trials in the development of new treatments, involving some scientific, statistical, and practical considerations. We elucidate some aspects of non-inferiority trials that contribute to the validity of the results. The unique design features and methodology of non-inferiority trials are summarized and key findings to consider when evaluating a non-inferiority trial are illustrated.
引用
收藏
页码:159 / 165
页数:7
相关论文
共 25 条
[1]   Non-inferiority Trial Design in Drug Development: A Primer for Cardiovascular Healthcare Professionals [J].
Angeli, Fabio ;
Verdecchia, Paolo ;
Reboldi, Gianpaolo .
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2020, 20 (03) :229-238
[2]  
Armitage P., 2001, STAT METHODS MED RES, V4th
[3]   A COMPARISON OF STATISTICAL-METHODS FOR COMBINING EVENT RATES FROM CLINICAL-TRIALS [J].
BERLIN, JA ;
LAIRD, NM ;
SACKS, HS ;
CHALMERS, TC .
STATISTICS IN MEDICINE, 1989, 8 (02) :141-151
[4]   Noninferiority Designed Cardiovascular Trials in Highest-Impact Journals Main Findings, Methodological Quality, and Time Trends [J].
Bikdeli, Behnood ;
Welsh, John W. ;
Akram, Yasir ;
Punnanithinont, Natdanai ;
Lee, Ike ;
Desai, Nihar R. ;
Kaul, Sanjay ;
Stone, Gregg W. ;
Ross, Joseph S. ;
Krumholz, Harlan M. .
CIRCULATION, 2019, 140 (05) :379-389
[5]   The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans [J].
Blech, Stefan ;
Ebner, Thomas ;
Ludwig-Schwellinger, Eva ;
Stangier, Joachim ;
Roth, Willy .
DRUG METABOLISM AND DISPOSITION, 2008, 36 (02) :386-399
[6]  
Center for Biologics Evaluation and Research (CBER) Center for Drug Evaluation and Research (CDER) Food and Drug Administration U.S. Department of Health and Human Services, GUID IND NON CLIN TR
[7]   Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].
Connolly, Stuart J. ;
Ezekowitz, Michael D. ;
Yusuf, Salim ;
Eikelboom, John ;
Oldgren, Jonas ;
Parekh, Amit ;
Pogue, Janice ;
Reilly, Paul A. ;
Themeles, Ellison ;
Varrone, Jeanne ;
Wang, Susan ;
Alings, Marco ;
Xavier, Denis ;
Zhu, Jun ;
Diaz, Rafael ;
Lewis, Basil S. ;
Darius, Harald ;
Diener, Hans-Christoph ;
Joyner, Campbell D. ;
Wallentin, Lars .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151
[8]  
European Medicines Agency, 2005, PREAUTH EV MED HUM
[9]   GENERAL DESIGN ISSUES IN EFFICACY, EQUIVALENCY AND SUPERIORITY TRIALS [J].
FLEISS, JL .
JOURNAL OF PERIODONTAL RESEARCH, 1992, 27 (04) :306-313
[10]   Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis [J].
Hart, RG ;
Benavente, O ;
McBride, R ;
Pearce, LA .
ANNALS OF INTERNAL MEDICINE, 1999, 131 (07) :492-+